NASDAQ:CORT - Corcept Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$12.26 -0.01 (-0.08 %)
(As of 04/25/2019 03:45 AM ET)
Previous Close$12.27
Today's Range$12.23 - $12.43
52-Week Range$9.14 - $20.00
Volume330,460 shs
Average Volume1.35 million shs
Market Capitalization$1.41 billion
P/E Ratio20.43
Dividend YieldN/A
Beta1.27
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant that is in Phase III clinical trial to treat patients with Cushing's syndrome; and Abraxane in combination with relacorilant, which is in Phase II clinical trial to treat metastatic ovarian cancer, as well as in Phase I/II clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator CORT125281 combined with Xtandi that is in open label Phase I/II trial to treat patients with metastatic castration-resistant prostate cancer; CORT118335 selective cortisol modulator for the treatment of antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

Receive CORT News and Ratings via Email

Sign-up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:CORT
CUSIP21835210
Phone650-327-3270

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$251.25 million
Cash Flow$0.6714 per share
Book Value$2.39 per share

Profitability

Net Income$75.41 million

Miscellaneous

Employees166
Market Cap$1.41 billion
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable

Corcept Therapeutics (NASDAQ:CORT) Frequently Asked Questions

What is Corcept Therapeutics' stock symbol?

Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) released its quarterly earnings data on Monday, February, 25th. The biotechnology company reported $0.18 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.04. The biotechnology company had revenue of $66.80 million for the quarter, compared to analyst estimates of $70.43 million. Corcept Therapeutics had a return on equity of 30.30% and a net margin of 29.97%. Corcept Therapeutics's revenue was up 25.3% compared to the same quarter last year. During the same period last year, the firm posted $0.77 earnings per share. View Corcept Therapeutics' Earnings History.

When is Corcept Therapeutics' next earnings date?

Corcept Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Corcept Therapeutics.

What guidance has Corcept Therapeutics issued on next quarter's earnings?

Corcept Therapeutics updated its FY 2019 earnings guidance on Monday, February, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $285-315 million.

What price target have analysts set for CORT?

3 brokerages have issued twelve-month price objectives for Corcept Therapeutics' shares. Their predictions range from $11.00 to $14.00. On average, they anticipate Corcept Therapeutics' stock price to reach $12.00 in the next twelve months. This suggests that the stock has a possible downside of 2.1%. View Analyst Price Targets for Corcept Therapeutics.

What is the consensus analysts' recommendation for Corcept Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Corcept Therapeutics.

What are Wall Street analysts saying about Corcept Therapeutics stock?

Here are some recent quotes from research analysts about Corcept Therapeutics stock:
  • 1. According to Zacks Investment Research, "Corcept is making good progress with its Cushing's syndrome drug, Korlym. Notably, its efforts to expand Korlym’s label are encouraging and should boost the drug’s commercial potential significantly. The company is also making attempts to develop its pipeline with its most advanced candidate relacorilant (CORT125134), currently under evaluation in a phase II study for Cushing's syndrome. The successful development of its pipeline candidates will further boost the company’s portfolio and lead to increased sales. However, Corcept’s share price movement shows that the stock has underperformed the industry year to date. Moreover, Corcept is solely dependent on Korlym for growth. A decline in Korlym sales will hinder the company’s growth prospects in the future quarters." (4/5/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We are Neutral on CORT with a 12-month price target of $17 based on value from Korlym. Yesterday, after market close, Corcept reported 3Q18 revenues of $64.4M & cash of $196.7M. Our model projects current cash & Korlym profits to fund operations through the P3 study of Relacorilant in Cushing’s as well as signal-seeking studies underway with several earlier candidates. 3Q call centered on sustainability of Korlym sales growth and Rela’s P3. Korlym sales grew 51% in 3Q18 compared to 3Q17. We believe that this growth is a result of the company’s effective outreach and education efforts to physicians that has yet to peak as there are prescribers it has yet to engage." (11/2/2018)

Has Corcept Therapeutics been receiving favorable news coverage?

News coverage about CORT stock has been trending somewhat positive this week, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Corcept Therapeutics earned a daily sentiment score of 1.3 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the company's share price in the next several days.

Are investors shorting Corcept Therapeutics?

Corcept Therapeutics saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 25,204,409 shares, an increase of 0.7% from the March 15th total of 25,028,508 shares. Based on an average trading volume of 759,764 shares, the short-interest ratio is currently 33.2 days. Currently, 24.4% of the company's stock are sold short. View Corcept Therapeutics' Current Options Chain.

Who are some of Corcept Therapeutics' key competitors?

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), CA (CA), BlackRock (BLK), NVIDIA (NVDA), Alibaba Group (BABA), Endologix (ELGX), Celgene (CELG), AbbVie (ABBV), Advanced Micro Devices (AMD) and Energy Transfer LP Unit (ET).

Who are Corcept Therapeutics' key executives?

Corcept Therapeutics' management team includes the folowing people:
  • Dr. Joseph K. Belanoff, Co-Founder, Pres, CEO & Director (Age 62)
  • Mr. Gary Charles Robb, CFO & Sec. (Age 56)
  • Mr. Sean Maduck, Sr. VP of Commercial (Age 42)
  • Dr. Christopher Shayne James M.D., Director of Investor Relations
  • Dr. Hazel Hunt Ph.D., Sr. VP of Research

Who are Corcept Therapeutics' major shareholders?

Corcept Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (7.30%), Peregrine Capital Management LLC (0.42%), Tealwood Asset Management Inc. (0.13%) and Valeo Financial Advisors LLC (0.02%). Company insiders that own Corcept Therapeutics stock include David L Mahoney, G Leonard Baker Jr, Gary Charles Robb, Joseph K Belanoff, Renee D Gala, Robert S Fishman and Sean Maduck. View Institutional Ownership Trends for Corcept Therapeutics.

Which major investors are selling Corcept Therapeutics stock?

CORT stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC and Peregrine Capital Management LLC. Company insiders that have sold Corcept Therapeutics company stock in the last year include G Leonard Baker Jr, Gary Charles Robb, Joseph K Belanoff, Robert S Fishman and Sean Maduck. View Insider Buying and Selling for Corcept Therapeutics.

Which major investors are buying Corcept Therapeutics stock?

CORT stock was bought by a variety of institutional investors in the last quarter, including Tealwood Asset Management Inc. and Valeo Financial Advisors LLC. Company insiders that have bought Corcept Therapeutics stock in the last two years include G Leonard Baker Jr, Gary Charles Robb and Renee D Gala. View Insider Buying and Selling for Corcept Therapeutics.

How do I buy shares of Corcept Therapeutics?

Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corcept Therapeutics' stock price today?

One share of CORT stock can currently be purchased for approximately $12.26.

How big of a company is Corcept Therapeutics?

Corcept Therapeutics has a market capitalization of $1.41 billion and generates $251.25 million in revenue each year. The biotechnology company earns $75.41 million in net income (profit) each year or $0.60 on an earnings per share basis. Corcept Therapeutics employs 166 workers across the globe.

What is Corcept Therapeutics' official website?

The official website for Corcept Therapeutics is http://www.corcept.com.

How can I contact Corcept Therapeutics?

Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-327-3270 or via email at [email protected]


MarketBeat Community Rating for Corcept Therapeutics (NASDAQ CORT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  389 (Vote Outperform)
Underperform Votes:  316 (Vote Underperform)
Total Votes:  705
MarketBeat's community ratings are surveys of what our community members think about Corcept Therapeutics and other stocks. Vote "Outperform" if you believe CORT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CORT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel